■钙通道被认为具有作为帕金森病(PD)神经保护治疗的药物靶标的巨大潜力,但以往的研究结果不一致.
■本研究旨在进行系统评价和荟萃分析,以评估使用钙通道阻滞剂(CCB)与PD风险和进展之间的关系。
■诸如“帕金森氏病”之类的术语,\'PD\',\'钙通道阻滞剂\',和“CCB”用于搜索2023年5月1日之前在英语数据库中发表的文献,包括PubMed,Embase,和Cochrane图书馆,用于CCB和PD的研究。使用ReviewManager5.3软件进行数据分析。
■初步检索到190篇文献,通过消除重复项排除了177件文学作品,阅读摘要,阅读全文共有9项研究最终纳入CCB和PD风险的荟萃分析,5项研究纳入CCB和PD进展的系统评价.共有2,961,695名参与者被纳入荟萃分析。由于存在显著的异质性,采用随机效应模型进行分析。荟萃分析的主要结果表明,使用CCB可以降低PD的风险(相对风险0.78,95%置信区间0.62-0.99)。
■使用CCB与PD风险显著降低相关。CCB的使用是否对PD有改善疾病的作用需要进一步研究。
■PROSPERO:CRD42024508242。
UNASSIGNED: The calcium channel has been considered to have great potential as a drug target for neuroprotective therapy in Parkinson\'s disease (PD), but previous studies yielded inconsistent results.
UNASSIGNED: This study aimed to conduct a systematic
review and meta-analysis to assess the relationship between using calcium channel blockers (CCBs) and the risk and progression of PD.
UNASSIGNED: The terms such as \'Parkinson\'s disease\', \'PD\', \'calcium channel blockers\', and \'CCB\' were used to search the literature published before 1 May 2023 in English databases, including PubMed, Embase, and Cochrane Library, for studies on CCB and PD. Data analysis was performed using
Review Manager 5.3 software.
UNASSIGNED: A total of 190 works of literature were preliminarily retrieved, and 177 works of literature were excluded by eliminating duplicates, reading abstracts, and reading full texts. A total of nine studies were finally included in the meta-analysis of the CCB and the risk of PD, and five studies were included in the systematic
review of the CCB and the progression of PD. A total of 2,961,695 participants were included in the meta-analysis. The random-effects model was used for analysis due to significant heterogeneity. The main results of the meta-analysis showed that the use of CCB could reduce the risk of PD (relative risk 0.78, 95% confidence interval 0.62-0.99).
UNASSIGNED: CCB use was associated with a significantly reduced risk of PD. Whether CCB use has a disease-modifying effect on PD needs further study.
UNASSIGNED: PROSPERO: CRD42024508242.